{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:10:08Z","timestamp":1790770208412,"version":"4.1.0"},"reference-count":20,"publisher":"Bioscientifica","license":[{"start":{"date-parts":[[2018,8,23]],"date-time":"2018-08-23T00:00:00Z","timestamp":1534982400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/deed.en_GB"}],"content-domain":{"domain":["edm.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,8,23]]},"abstract":"Summary<\/jats:title>\n Adrenocortical carcinoma (ACC) during childhood is a rare malignant tumor that frequently results in glucocorticoid and\/or androgen excess. When there are signs of microscopic or macroscopic residual disease, adjuvant therapy is recommended with mitotane, an adrenolytic and cytotoxic drug. In addition to the anticipated side effect of adrenal insufficiency, mitotane is known to cause gynecomastia and hypothyroidism in adults. It has never been reported to cause precocious puberty. A 4-year-old girl presented with a 6-week history of virilization and elevated androgen levels and 1-year advancement in bone age. Imaging revealed a right adrenal mass, which was subsequently surgically excised. Histology revealed ACC with multiple unfavorable features, including high mitotic index, capsular invasion and atypical mitoses. Adjuvant chemotherapy was started with mitotane, cisplatin, etoposide and doxorubicin. She experienced severe gastrointestinal side effects and symptomatic adrenal insufficiency, which occurred despite physiological-dose corticosteroid replacement. She also developed hypothyroidism that responded to treatment with levothyroxine and peripheral precocious puberty (PPP) with progressive breast development and rapidly advancing bone age. Five months after discontinuing mitotane, her adrenal insufficiency persisted and she developed secondary central precocious puberty (CPP). This case demonstrates the diverse endocrine complications associated with mitotane therapy, which contrast with the presentation of ACC itself. It also provides the first evidence that the known estrogenic effect of mitotane can manifest as PPP.<\/jats:p>\n \n Learning points:<\/jats:title>\n \n \n Adrenocortical carcinoma is an important differential diagnosis for virilization in young children<\/jats:p>\n <\/jats:list-item>\n \n Mitotane is a chemotherapeutic agent that is used to treat adrenocortical carcinoma and causes adrenal necrosis<\/jats:p>\n <\/jats:list-item>\n \n Mitotane is an endocrine disruptor. In addition to the intended effect of adrenal insufficiency, it can cause hypothyroidism, with gynecomastia also reported in adults.<\/jats:p>\n <\/jats:list-item>\n \n Patients taking mitotane require very high doses of hydrocortisone replacement therapy because mitotane interferes with steroid metabolism. This effect persists after mitotane therapy is completed<\/jats:p>\n <\/jats:list-item>\n \n In our case, mitotane caused peripheral precocious puberty, possibly through its estrogenic effect.<\/jats:p>\n <\/jats:list-item>\n <\/jats:list>\n <\/jats:sec>","DOI":"10.1530\/edm-18-0059","type":"journal-article","created":{"date-parts":[[2018,8,23]],"date-time":"2018-08-23T09:26:36Z","timestamp":1535016396000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-2","source":"Crossref","is-referenced-by-count":13,"title":["Mitotane in the treatment of childhood adrenocortical carcinoma: a potent endocrine disruptor"],"prefix":"10.1530","volume":"2018","author":[{"given":"Philip D","family":"Oddie","sequence":"first","affiliation":[{"name":"1Medical School, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin B","family":"Albert","sequence":"additional","affiliation":[{"name":"2Liggins Institute, University of Auckland, Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul L","family":"Hofman","sequence":"additional","affiliation":[{"name":"2Liggins Institute, University of Auckland, Auckland, New Zealand"},{"name":"3Starship Children\u2019s Health, Auckland District Health Board, Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Jefferies","sequence":"additional","affiliation":[{"name":"3Starship Children\u2019s Health, Auckland District Health Board, Auckland, New Zealand"},{"name":"3Starship Children\u2019s Health, Auckland District Health Board, Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Laughton","sequence":"additional","affiliation":[{"name":"3Starship Children\u2019s Health, Auckland District Health Board, Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippa J","family":"Carter","sequence":"additional","affiliation":[{"name":"3Starship Children\u2019s Health, Auckland District Health Board, Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","reference":[{"key":"ref141","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/cen.12868","article-title":"Mitotane treatment in patients with adrenocortical cancer causes central hypothyroidism","volume":"84","year":"2016","journal-title":"Clinical Endocrinology"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1210\/jc.2005-2157","article-title":"Mitotane has an estrogenic effect on sex hormone- binding globulin and corticosteroid-binding globulin in humans","volume":"91","year":"2006","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.beem.2008.10.008","article-title":"Clinical management of adrenocortical carcinoma","volume":"23","year":"2009","journal-title":"Best Practice and Research Clinical Endocrinology and Metabolism"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1055\/s-0032-1327579","article-title":"Systemic treatment of adrenocortical carcinoma in children: data from the German GPOH-MET 97 trial","volume":"224","year":"2012","journal-title":"Klinische P\u00e4diatrie"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/cen.12868","article-title":"Mitotane treatment in patients with adrenocortical cancer causes central hypothyroidism","volume":"84","year":"2016","journal-title":"Clinical Endocrinology"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1055\/s-0032-1327579","article-title":"Systemic treatment of adrenocortical carcinoma in children: data from the German GPOH-MET 97 trial","volume":"224","year":"2012","journal-title":"Klinische P\u00e4diatrie"},{"key":"ref181","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1210\/jc.2005-2157","article-title":"Mitotane has an estrogenic effect on sex hormone- binding globulin and corticosteroid-binding globulin in humans","volume":"91","year":"2006","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.ejca.2004.01.031","article-title":"Childhood adrenocortical tumours","volume":"40","year":"2004","journal-title":"European Journal of Cancer"},{"key":"ref161","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1530\/acta.0.1240526","article-title":"Mitotane increases the blood levels of hormone-binding proteins","volume":"124","year":"1991","journal-title":"Acta Endocrinologica"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.beem.2008.10.008","article-title":"Clinical management of adrenocortical carcinoma","volume":"23","year":"2009","journal-title":"Best Practice and Research Clinical Endocrinology and Metabolism"},{"key":"ref01","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.ejca.2004.01.031","article-title":"Childhood adrenocortical tumours","volume":"40","year":"2004","journal-title":"European Journal of Cancer"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1210\/jc.2012-2851","article-title":"Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5\u03b1-reductase, explaining the need for personalized glucocorticoid and androgen replacement","volume":"98","year":"2013","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S2213-8587(15)00380-0","article-title":"Causes, diagnosis, and treatment of central precocious puberty","volume":"4","year":"2016","journal-title":"Lancet Diabetes and Endocrinology"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1530\/acta.0.1240526","article-title":"Mitotane increases the blood levels of hormone-binding proteins","volume":"124","year":"1991","journal-title":"Acta Endocrinologica"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1056\/NEJMoa063360","article-title":"Adjuvant mitotane treatment for adrenocortical carcinoma","volume":"356","year":"2007","journal-title":"New England Journal of Medicine"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1210\/jc.2012-2851","article-title":"Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5\u03b1-reductase, explaining the need for personalized glucocorticoid and androgen replacement","volume":"98","year":"2013","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref171","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1210\/en.2009-1404","article-title":"Therapeutic concentrations of mitotane (o,p\u2019-DDD) inhibit thyrotroph cell viability and TSH expression and secretion in a mouse cell line model","volume":"151","year":"2010","journal-title":"Endocrinology"},{"key":"ref191","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S2213-8587(15)00380-0","article-title":"Causes, diagnosis, and treatment of central precocious puberty","volume":"4","year":"2016","journal-title":"Lancet Diabetes and Endocrinology"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1210\/en.2009-1404","article-title":"Therapeutic concentrations of mitotane (o,p\u2019-DDD) inhibit thyrotroph cell viability and TSH expression and secretion in a mouse cell line model","volume":"151","year":"2010","journal-title":"Endocrinology"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1056\/NEJMoa063360","article-title":"Adjuvant mitotane treatment for adrenocortical carcinoma","volume":"356","year":"2007","journal-title":"New England Journal of Medicine"}],"container-title":["Endocrinology, Diabetes & Metabolism Case Reports"],"original-title":[],"link":[{"URL":"https:\/\/edm.bioscientifica.com\/view\/journals\/edm\/2018\/1\/EDM18-0059.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/edm.bioscientifica.com\/downloadpdf\/journals\/edm\/2018\/1\/EDM18-0059.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:46:52Z","timestamp":1784555212000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.bioscientifica.com\/edm\/article\/3690"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,23]]},"references-count":20,"URL":"https:\/\/doi.org\/10.1530\/edm-18-0059","relation":{},"ISSN":["2052-0573"],"issn-type":[{"value":"2052-0573","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,23]]}}}